How have BCDAW shares performed in 2024?

BioCardia's stock was trading at $0.0125 at the beginning of 2024. Since then, BCDAW stock has increased by 8.0% and is now trading at $0.0135. View the best growth stocks for 2024 here .

How do I buy shares of BioCardia?

Shares of BCDAW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:BCDAW

BioCardia (BCDAW) Stock Price, News & Analysis

→ Who are Nvidia’s New Silent Partners? (From Weiss Ratings) (Ad)

Free BCDAW Stock Alerts

$0.01

0.00 (0.00%)

(As of 05/31/2024 ET)

Compare

Today's Range: $0.0135
▼
$0.0135
50-Day Range: $0.01
▼
$0.03
52-Week Range: $0.01
▼
$1.06

Volume: 38 shs
Average Volume: 12,840 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Competitors Financials SEC Filings Trends

Get BioCardia alerts:

Ad Crypto 101 Media

The #1 Crypto That You Don’t Own… Yet

There’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay attention to above all others: Venture capital firms. You want to follow venture capital money into cryptocurrencies before anyone gets word of what’s happening.

Click here for all the details…

About BioCardia Stock (NASDAQ:BCDAW)

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its leading product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. BioCardia, Inc. is based in Sunnyvale, California.

BCDAW Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BCDAW Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com

Receive BCDAW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioCardia and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NASDAQ:BCDAW
CUSIP: N/A
CIK: 925741
Web: www.biocardia.com
Phone: 16502260120
Fax: N/A
Employees: 16
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: $468,000.00
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Dr. Peter A. Altman Ph.D. (Age 57)
CEO, President & Director
Comp: $515.51k
Mr. David McClung (Age 61)
Chief Financial Officer
Comp: $370.86k
Mr. Edward M. Gillis (Age 62)
Senior Vice President of Devices
Comp: $263.1k

Key Competitors

View All Competitors

BCDAW Stock Analysis - Frequently Asked Questions

How have BCDAW shares performed in 2024?: BioCardia's stock was trading at $0.0125 at the beginning of 2024. Since then, BCDAW stock has increased by 8.0% and is now trading at $0.0135.
View the best growth stocks for 2024 here.
How do I buy shares of BioCardia?: Shares of BCDAW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BCDAW) was last updated on 6/1/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial